Literature DB >> 26363922

Advances in therapeutics for chronic hepatitis B.

Ninghan Yang1, Antonio Bertoletti2,3.   

Abstract

Chronic hepatitis B infection remains a major disease burden globally, and leads to high risk of hepatocellular carcinoma development. Current therapies of nucleot(s)ide analogues and interferon alpha treatment remain limited in their efficacy. Several key findings in the hepatitis B virus (HBV) life cycle have led to the development of novel antiviral drugs to inhibit viral replication and persistence. In addition, recent studies on HBV-specific innate and adaptive immune responses have advanced development of immunotherapy to restore immune mediated virus control in chronic hepatitis B patients. In this review, we discuss potential new therapeutic strategies targeting HBV or the host immune system that might lead to a sustained cure for chronic hepatitis B.

Entities:  

Keywords:  Antiviral drugs; Chronic hepatitis B; Hepatitis B virus; Immunity; Immunotherapy; Viral replication

Mesh：

Substances：

Year:  2015        PMID： 26363922     DOI： 10.1007/s12072-015-9661-x

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


  95 in total

Review 1.  Hepatitis B virus infection.

Authors:  Christian Trépo; Henry L Y Chan; Anna Lok
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

2.  Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.

Authors:  Bertram Bengsch; Bianca Martin; Robert Thimme
Journal:  J Hepatol       Date:  2014-07-10       Impact factor: 25.083

3.  Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience.

Authors:  P Rendi-Wagner; M Kundi; H Stemberger; G Wiedermann; H Holzmann; M Hofer; K Wiesinger; H Kollaritsch
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

4.  Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.

Authors:  Adam J Gehring; Muzlifah Haniffa; Patrick T Kennedy; Zi Zong Ho; Carolina Boni; Amanda Shin; Nasirah Banu; Adeline Chia; Seng Gee Lim; Carlo Ferrari; Florent Ginhoux; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

5.  Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis.

Authors:  T Gerelsaikhan; J E Tavis; V Bruss
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans.

Authors:  Andreas Schulze; Philippe Gripon; Stephan Urban
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

7.  Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.

Authors:  Patrick Marcellin; Ferruccio Bonino; George K K Lau; Patrizia Farci; Cihan Yurdaydin; Teerha Piratvisuth; Rui Jin; Selim Gurel; Zhi-Meng Lu; Jian Wu; Matei Popescu; Stephanos Hadziyannis
Journal:  Gastroenterology       Date:  2009-03-19       Impact factor: 22.682

8.  Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.

Authors:  Jia Liu; Ejuan Zhang; Zhiyong Ma; Weimin Wu; Anna Kosinska; Xiaoyong Zhang; Inga Möller; Pia Seiz; Dieter Glebe; Baoju Wang; Dongliang Yang; Mengji Lu; Michael Roggendorf
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

9.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.

Authors:  Su-Ru Lin; Hung-Chih Yang; Yi-Ting Kuo; Chun-Jen Liu; Ta-Yu Yang; Ku-Chun Sung; You-Yu Lin; Hurng-Yi Wang; Chih-Chiang Wang; Yueh-Chi Shen; Fang-Yi Wu; Jia-Horng Kao; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-19       Impact factor: 10.183

10.  Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?

Authors:  Antonio Bertoletti; Adam J Gehring
Journal:  PLoS Pathog       Date:  2013-12-19       Impact factor: 6.823
View more
  10 in total

Review 1.  Impact of etiological treatment on prognosis.

Authors:  Chien-Wei Su; Ying-Ying Yang; Han-Chieh Lin
Journal:  Hepatol Int       Date:  2017-07-12       Impact factor: 6.047

2.  An OX40/OX40L interaction directs successful immunity to hepatitis B virus.

Authors:  Jean Publicover; Anuj Gaggar; Jillian M Jespersen; Ugur Halac; Audra J Johnson; Amanda Goodsell; Lia Avanesyan; Stephen L Nishimura; Meghan Holdorf; Keith G Mansfield; Joyce Bousquet Judge; Arya Koshti; Michael Croft; Adil E Wakil; Philip Rosenthal; Eric Pai; Stewart Cooper; Jody L Baron
Journal:  Sci Transl Med       Date:  2018-03-21       Impact factor: 17.956

3.  Effect of Hepatocyte Targeting Nanopreparation Syringopicroside on Duck Hepatitis B Virus and Evaluation of Its Safety.

Authors:  X W Zhang; M C Li; J J Dou
Journal:  Bull Exp Biol Med       Date:  2022-03-30       Impact factor: 0.804

4.  Interferon-α inhibits cell migration and invasion and induces the expression of antiviral proteins in Huh-7 cells transfected with hepatitis B virus X gene-expressing lentivirus.

Authors:  Qian Yang; Xiao-Peng Li; Yuan-Bin Zhong; Tian-Xin Xiang; Lun-Li Zhang
Journal:  Exp Ther Med       Date:  2017-10-11       Impact factor: 2.447

5.  Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs.

Authors:  Mohube Betty Maepa; Abdullah Ely; Wayne Grayson; Patrick Arbuthnot
Journal:  Mol Ther Nucleic Acids       Date:  2017-04-13

6.  EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation.

Authors:  Chong J Gan; Wen F Li; Chun N Li; Ling L Li; Wen Y Zhou; Xiao M Peng
Journal:  Biochem Biophys Rep       Date:  2020-04-18

Review 7.  The state of gene therapy research in Africa, its significance and implications for the future.

Authors:  P Arbuthnot; M B Maepa; A Ely; M S Pepper
Journal:  Gene Ther       Date:  2017-07-10       Impact factor: 5.250

8.  Clinical Efficacy and Safety of Tenofovir in the Treatment of Patients with Chronic Hepatitis B.

Authors:  Feng He; Zhongjiang Xia; Hui Wang; Jinjun Zhu; Laiwen Hu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-21       Impact factor: 2.650

9.  Fuzheng Huayu Recipe and its active compounds inhibited HBeAg production by promoting TOMM34 gene expression in HBV-infected hepatocytes.

Authors:  Lu Xing; Rui Zeng; Kai Huang; Jingbo Xue; Hongliang Liu; Zhimin Zhao; Yuan Peng; Xudong Hu; Chenghai Liu
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

Review 10.  HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review.

Authors:  Giuseppe Gentile; Guido Antonelli
Journal:  Viruses       Date:  2019-11-10       Impact factor: 5.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.